GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » Capex-to-Operating-Cash-Flow

Staar Surgical Co (Staar Surgical Co) Capex-to-Operating-Cash-Flow : 0.24 (As of Mar. 2024)


View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Staar Surgical Co's Capital Expenditure for the three months ended in Mar. 2024 was $-5.20 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2024 was $21.68 Mil.

Hence, Staar Surgical Co's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2024 was 0.24.


Staar Surgical Co Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Staar Surgical Co's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co Capex-to-Operating-Cash-Flow Chart

Staar Surgical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 0.40 0.31 0.51 1.25

Staar Surgical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.10 0.24

Competitive Comparison of Staar Surgical Co's Capex-to-Operating-Cash-Flow

For the Medical Instruments & Supplies subindustry, Staar Surgical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staar Surgical Co's Capex-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Staar Surgical Co's Capex-to-Operating-Cash-Flow falls into.



Staar Surgical Co Capex-to-Operating-Cash-Flow Calculation

Staar Surgical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-18.188) / 14.594
=1.25

Staar Surgical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-5.202) / 21.68
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staar Surgical Co  (NAS:STAA) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Staar Surgical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Staar Surgical Co (Staar Surgical Co) Business Description

Traded in Other Exchanges
Address
25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust officer: Chief Operating Officer 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna officer: Chief Clinical, Regulatory, C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday officer: V.P., Research & Development 1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme officer: Senior VP, Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese officer: VP, Global Marketing 1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason director 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten officer: VP, General Counsel 1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams officer: Chief Financial Officer C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer officer: VP, International Marketing 1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman director
Graydon C. Hansen officer: Sr. VP, Global Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida officer: VP, Global Clinical, Medical 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630